| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 874.36M | 908.29M | 975.82M | 899.92M | 770.46M | 648.01M |
| Gross Profit | 182.57M | 189.25M | 202.10M | 174.93M | 166.86M | 154.20M |
| EBITDA | 8.21M | -381.00K | 45.06M | 31.18M | 52.10M | 28.64M |
| Net Income | -32.04M | -16.52M | -5.18M | -14.06M | 3.41M | -7.95M |
Balance Sheet | ||||||
| Total Assets | 632.08M | 621.56M | 679.90M | 652.11M | 665.40M | 621.41M |
| Cash, Cash Equivalents and Short-Term Investments | 53.99M | 71.83M | 40.84M | 54.80M | 85.55M | 73.92M |
| Total Debt | 180.66M | 208.06M | 203.01M | 179.85M | 184.12M | 159.11M |
| Total Liabilities | 380.88M | 376.30M | 392.18M | 371.16M | 369.45M | 324.77M |
| Stockholders Equity | 251.19M | 245.26M | 287.72M | 280.94M | 295.95M | 296.63M |
Cash Flow | ||||||
| Free Cash Flow | 23.52M | 23.45M | -33.55M | -24.80M | -63.28M | -3.82M |
| Operating Cash Flow | 44.42M | 47.75M | 4.95M | 6.81M | -36.25M | 28.64M |
| Investing Cash Flow | -21.06M | -24.47M | -36.98M | -28.58M | 28.04M | -33.88M |
| Financing Cash Flow | -27.65M | 11.12M | 17.48M | -7.30M | 22.88M | 6.51M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $337.54M | 14.00 | 10.85% | ― | 6.83% | 46.38% | |
69 Neutral | $130.64M | 3.90 | 9.19% | ― | 16.72% | 5.35% | |
64 Neutral | $497.71M | -20.12 | -5.54% | ― | -3.20% | -257.73% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
59 Neutral | $247.41M | 105.64 | 0.94% | ― | 6.72% | ― | |
48 Neutral | $55.10M | -0.91 | -31.07% | ― | -23.26% | -259.03% | |
45 Neutral | $158.30M | -4.91 | -12.26% | ― | -4.91% | -331.53% |
On November 5, 2025, Stoneridge announced an amendment to its credit agreement, providing covenant relief and reducing borrowing capacity as part of its strategic financial management. The company reported third-quarter 2025 results with sales of $210.3 million and a net loss of $9.4 million, while highlighting significant growth in its MirrorEye product line and new program awards totaling over $185 million in estimated lifetime revenue. Despite macroeconomic challenges, Stoneridge continues to focus on long-term growth through strategic initiatives and product innovations.